1-3 of 3
Sara Farshchi-Zarabi, MD
Close
Sort by
Journal Articles

Remissions after Third Induction Chemotherapy for Primary Non-Responders with Acute Myeloid Leukemia (AML) Are Uncommon and Short-Lived

Sara Farshchi Zarabi, MD, Steven M. Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Dina Khalaf, BSc, MSc, MD, Andrzej Lutynski, MD, Mark D. Minden, MD PhD, Amr Rostom, MD, Anna Rydlewski, MD, Andre C. Schuh, MD FRCPC, Hassan Sibai, MD, Karen W.L. Yee, MD, Aaron D. Schimmer, MD PhD
Journal: Blood
Blood (2016) 128 (22): 2800.
https://doi.org/10.1182/blood.V128.22.2800.2800
Published: 2016
Journal Articles

Results of Salvage Autologous Stem Cell Transplantation (ASCT) for Relapsed Multiple Myeloma (MM) in the Era of Novel Agents: Outcome of Patients (Pts) Receiving Prior Bortezomib (BTZ)-Based Therapy

Sara Farshchi Zarabi, MD, Esther Masih-Khan, PhD, Christine Chen, Vishal Kukreti, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Donna Reece, MD
Journal: Blood
Blood (2016) 128 (22): 5821.
https://doi.org/10.1182/blood.V128.22.5821.5821
Published: 2016
Journal Articles

Newly Diagnosed Myeloma (MM) Patients (Pts) with High-Risk (HR) Cytogenetics By FISH: Is There a Role for Tandem Autologous Stem Cell Transplantation (ASCT)?

Sara Farshchi-Zarabi, MD, Gurdeep Parmar, MD, Esther Masih-Khan, PhD, Sophia Farooki, MD FRCPC, Christine Chen, MD FRCPC, Vishal Kukreti, MD FRCPC, Anca Prica, MD FRCPC, Rodger Tiedemann, MBChB, FRCPC, PhD, Suzanne Trudel, MD, Donna Reece
Journal: Blood
Blood (2015) 126 (23): 3176.
https://doi.org/10.1182/blood.V126.23.3176.3176
Published: 2015